Goldman Sachs Upgrades Alnylam Pharmaceuticals to Buy, Raises Price Target to $370
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has upgraded Alnylam Pharmaceuticals from Neutral to Buy and raised the price target from $198 to $370.
August 16, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has upgraded Alnylam Pharmaceuticals from Neutral to Buy and significantly raised the price target from $198 to $370.
The upgrade from a major financial institution like Goldman Sachs and the substantial increase in the price target are likely to positively impact Alnylam Pharmaceuticals' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100